Aldeyra Therapeutics, Inc.
ALDX
$5.14
-$0.09-1.72%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -44.63% | 54.23% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.48% | -37.10% | |||
| Operating Income | 2.48% | 37.10% | |||
| Income Before Tax | 1.63% | 37.19% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 1.63% | 37.19% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 1.63% | 37.19% | |||
| EBIT | 2.48% | 37.10% | |||
| EBITDA | 2.51% | 37.22% | |||
| EPS Basic | 1.87% | 37.50% | |||
| Normalized Basic EPS | 1.83% | 37.52% | |||
| EPS Diluted | 1.87% | 37.50% | |||
| Normalized Diluted EPS | 1.83% | 37.52% | |||
| Average Basic Shares Outstanding | 0.26% | 0.52% | |||
| Average Diluted Shares Outstanding | 0.26% | 0.52% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||